Hei, Mainz Biomed (NASDAQ: MYNZ) isn't putting all eggs in the CRC basket - their PancAlert blood test for pancreatic cancer is heating up fast. The finance card above shows it at $1.46, down a bit today, but this pipeline depth could change the game. Back in June 2025, they kicked off feasibility testing with Crown Bioscience to back up those killer discovery stats: 95% sensitivity and 98% specificity. Plus, snagged up to 50% funding from the government-backed ISB, slashing burn and shouting external buy-in.

For the uninitiated, MYNZ's chasing a multi-cancer diagnostics empire, with ColoAlert already rolling in Europe to tackle CRC. PancAlert hits a brutal gap - pancreatic cancer's survival sucks without early screening, so demand's huge.

Keep eyes on: feasibility results confirming those benchmarks, clinical trial blueprints, and partner buzz amid the screening void. If it pans out and funding flows, PancAlert adds a fat pipeline premium pre-CRC US data, flipping MYNZ from "one-trick pony" to full platform. Could this validated second asset pump multiples before ReconAAsense launches in 2026? Feels like undervalued upside to me.











MTEK ABAT INTJ MRUS INV IREN ZURA LRCX MSFT IRBT NUVB MGRX LGCY STX TLIH WKSP BIAF UBER HIND SNDL NFLX AEI BA VOR UPST SELX BKKT AMD CRWD SMR AXIL CNCK PLUT CHOW SAIH REFR AUID MELI HBNB OLB RGTI FLYX WMT CORZ SNPS GRWG SCYX KEN STEX IVDA ADVM NEUP IOBT TSLA GLXY APLT SPRU PAYS MGN ORCL SPCE CCL STKS FOFO UPB CVS TTNP ORKA CENX BURU SPHL BANL CRCL SYPR ASTL FSEA LV PMEC QBTS PLTS UMAC RCT EQX SNAP EL LPTX BMNR SNOW SEED GNSS FACT PYPL KPRX VFF FLY AIIO MSS NVDA SNWV ITP VSME MFH AVGO FLUT IQST CRWV CRM HOOD AREC LVTX WNW MSTR ESBA TSSI SOPH WAI PHIO TLRY JZXN DFLI MTEX USGO MTEN LUD WDC DNA ATMC INVZ SGLY YCBD ISPC MAPS BAFN SPAI YDES TBN KCHV ENTA CYCN EMPG MNMD APH SOFI GDEV CLIK DKNG QCLS TGE OPEN MNDR PAVS OXY PFE DUO

MYNZ's PancAlert: A Second Cancer Screening Beast in the Works?